NCT06881498 A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
| NCT ID | NCT06881498 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Bone Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-06-07 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-06-07 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prevention of perioperative anemia has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will improve postoperative hemoglobin levels when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.
Eligibility Criteria
Inclusion Criteria: 1. age 18 to 75 years; 2. undergoing elective bone tumor resection surgery; 3. preoperative hemoglobin ≥11 g/dL; Exclusion Criteria: 1. using a tourniquet; 2. palliative operation or minimally invasive surgery; 3. BMI\<18.5 or \>30Kg/m\^2; 4. international normalized ratio (INR) \>1.5 or platelet count \<100 × 10\^9/L; 5. cardiopulmonary insufficiency; 6. hepatic and renal dysfunction; 7. active infectious disease; 8. allergy to succinyl gelatin; 9. pregnancy; 10. declined participation in the study or declined blood transfusion
Frequently Asked Questions
Who can join the NCT06881498 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Bone Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06881498 currently recruiting?
Yes, NCT06881498 is actively recruiting participants. Visit ClinicalTrials.gov or contact Second Affiliated Hospital, School of Medicine, Zhejiang University to inquire about joining.
Where is the NCT06881498 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06881498 clinical trial?
NCT06881498 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 32 participants.